IDO Is Still A Valid Pathway For NewLink Genetics (NASDAQ:LUMO) | Seeking Alpha
INCB24360 (epacadostat) – All About Drugs
Structural Basis of Selective Human Indoleamine‐2,3‐dioxygenase 1 (hIDO1) Inhibition - Kassab - 2021 - ChemMedChem - Wiley Online Library
The State of IDO Inhibitor Combinations in the Treatment of Melanoma
Epacadostat - Wikipedia
Volker Schulz on Twitter: "So, will $NLNK's #indoximod, the #IDO inhibitor (that isn't really an IDO inhibitor) succeed, where #epacadostat failed? $INCY $MRK https://t.co/soLajZYdiR" / Twitter
Characterization of Apo‐Form Selective Inhibition of Indoleamine 2,3‐Dioxygenase** - Ortiz‐Meoz - 2021 - ChemBioChem - Wiley Online Library
Beyond PD-1 Immunotherapy in Malignant Melanoma | SpringerLink
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. - Abstract - Europe PMC
Epacadostat - Launch Insight, 2019 - Research and Markets
Biomedicines | Free Full-Text | Cancer Vaccines in Ovarian Cancer: How Can We Improve? | HTML
Frontiers | Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers | Oncology
INCB24360 (epacadostat) – All About Drugs
IDO Inhibitor Development Shows Fresh Signs of Life Across Tumor Types
Indoximod - an overview | ScienceDirect Topics
Targeting the IDO1 pathway in cancer: from bench to bedside | Journal of Hematology & Oncology | Full Text
Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab) | Business Wire
Tryptophan Metabolism as a Pharmacological Target: Trends in Pharmacological Sciences
IDO Is Still A Valid Pathway For NewLink Genetics (NASDAQ:LUMO) | Seeking Alpha
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry - MedChemComm (RSC Publishing) DOI:10.1039/C7MD00109F
Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1 | Oncotarget
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy - ScienceDirect
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy | Journal of Hematology & Oncology | Full Text
aacrindoximod
